Sinovac Biotech (SVA) Stock Price, News & Analysis

Company Overview

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Key Stats

• Today's Range: $6.47 to $6.47
• 50-Day Range: $6.47 to $6.47
• 52-Week Range: $5.73 to $8.75
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $644.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Sinovac Biotech Stock Analysis - MarketRank™

Sinovac Biotech scored higher than 18% of companies evaluated by MarketBeat, and ranked 848th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sinovac Biotech.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Sinovac Biotech has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of Sinovac Biotech has been sold short.

Short Interest Ratio / Days to Cover

Sinovac Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sinovac Biotech does not currently pay a dividend.

Dividend Growth

Sinovac Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.93

News Sentiment

Sinovac Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sinovac Biotech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sinovac Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.79% of the stock of Sinovac Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Sinovac Biotech has minimal institutional ownership at this time.

Company Calendar

• Today: 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SVA
• CIK: 1084201
• Web: www.sinovac.com
• Phone: 86-10-5693-1800
• Fax: 86-10-5693-1800
• Employees: 3,008
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 4.59
• Quick Ratio: 4.53

Sales & Book Value

• Annual Sales: $386.01 million
• Price / Sales: 1.67
• Cash Flow: $0.54 per share
• Price / Cash Flow: 11.89
• Book Value: $89.01 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 99,640,000
• Free Float: 86,894,000
• Market Cap: $644.67 million
• Optionable: Optionable
• Beta: 0.79